溫泳濤 王兆邦 趙一菊 梁秋亭 蔡杰
順鉑聯(lián)合吉西他濱與順鉑聯(lián)合紫杉醇治療晚期
非小細胞肺癌的療效分析
溫泳濤 王兆邦 趙一菊 梁秋亭 蔡 杰
廣東省東莞市第五人民醫(yī)院呼吸內(nèi)科,廣東東莞 523900
[摘要] 目的 探討順鉑聯(lián)合吉西他濱與順鉑聯(lián)合紫杉醇治療晚期非小細胞肺癌的療效。 方法 選擇我院2012年1月~2014年1月我院收治的非小細胞肺癌患者100例,隨機分為觀察組(吉西他濱+順鉑,GP組)和對照組(紫杉醇+順鉑,TP組),每組50例,兩組患者均每21天為一個周期,連用2個周期以上后觀察療效,比較兩組的毒副反應(yīng)。 結(jié)果 觀察組治療后的有效率達42.0%(21/50),高于對照組的有效率40%(20/50),但組間比較差異無統(tǒng)計學(xué)意義(P>0.05)。觀察組、對照組的Ⅲ+Ⅳ度白細胞減少率比較,差異存在顯著性(8% vs 30%,P<0.05)。觀察組、對照組的Ⅲ+Ⅳ度血小板減少率比較,差異存在顯著性(22% vs 4%,P<0.05)。觀察組和對照組血紅蛋白下降、惡心嘔吐、脫發(fā)、肝功能損害、腎功能損害的發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P>0.05)。 結(jié)論 順鉑聯(lián)合吉西他濱與順鉑聯(lián)合紫杉醇治療晚期非小細胞肺癌的療效相似,毒副作用各異且均可耐受,均為治療晚期非小細胞肺癌效果較好的治療方案。
[關(guān)鍵詞] 非小細胞肺癌;晚期;順鉑;吉西他濱;紫杉醇
[中圖分類號] R734.2 [文獻標(biāo)識碼] B [文章編號] 1673-9701(2015)03-0074-03
Analysis of curative effect of cisplatin combined with gemcitabine and cisplatin plus paclitaxel in the treatment of advanced non-small cell lung cancer
WEN Yongtao WANG Zhaobang ZHAO Yiju LIANG Qiuting CAI Jie
Respiratory Department of Internal Medicine,the Fifth People's Hospital of Dongguan City in Guangdong Province, Dongguan 523900,China
[Abstract] Objective To investigate the curative effect of cisplatin combined with gemcitabine and cisplatin plus paclitaxel in the treatment of advanced non-small cell lung cancer. Methods All 100 patients with non-small cell lung cancer in our hospital from January 2012 to January 2014 in our hospital, randomly divided into observation group (gemcitabine+cisplatin, GP group) and control group (paclitaxel+cisplatin, TP group), each group had 50 cases, two groups of patients every 21 days for a cycle, observed curative effect after 2 cycles, toxic and adverse reaction were compared between the two groups. Results The effective rate of the observation group after treatment was 42.0%(21/50),was higher than that of the control group 40% (20/50), but there was no significant difference (P>0.05). Conclusion Curative effect of cisplatin combined with gemcitabine and cisplatin plus paclitaxel in the treatment of advanced non-small cell lung cancer is similar, the poisonous side effect is different and can be tolerated, for the treatment of advanced non-small cell lung cancer treatment plan better.
[Key words] Non-small cell lung cancer; Advanced; Cisplatin; Gemcitabine; Paclitaxel